icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022
Back grey_arrow_rt.gif
 
 
 
The bispecific anti-FGFR1/KLB agonist antibody
bFKB1 attenuates non-alcoholic
steatohepatitis and atherosclerosis in Ldlr-/-.Leiden mice

 
 
  AASLD 2022 nov 4-8
 
Jos A. Inia1,2,3, Anita M. van den Hoek1, Geurt Stokman1, Joline Attema1, Christa de Ruiter1, Martien Caspers4, Lars Verschuren4, J. Wouter Jukema2,3, Maria Wilson5, Hans M.G. Princen1, Mark Chen5,6, Martine C. Morrison1 1 Metabolic Health Research, TNO Leiden, The Netherlands, 2 Department of Cardiology and 3 Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center Leiden, The Netherlands, 4 Microbiology and Systems Biology, TNO Zeist, The Netherlands, 5 Genentech, South San Francisco, USA, 6 Takeda Pharmaceuticals, San Diego

1122221

1122222

1122223

1122224